Oura is heading to Nasdaq with a potential $2.2 billion IPO, but the biggest story may not be how much money the company raises. It is how much existing investors are cashing out.
The smart ring maker plans to offer 50 million shares at $40 to $44 each, putting the potential value of the offering at about $2.2 billion at the top end.
But there is an important detail in the filing.
Around 73% of the shares being offered are coming from existing shareholders.
That means a large part of this IPO is effectively giving early investors a chance to turn years of private-market ownership into public-market cash.
Forerunner Ventures is making the biggest exit
Among the investors selling shares, Forerunner Ventures stands out by a wide margin.
The venture capital firm owns about 9.3% of Oura and plans to sell its entire stake of nearly 28.7 million shares in the IPO.
At the midpoint price of $42 per share, that stake would be worth roughly $1.2 billion before underwriting discounts.
The numbers become even more striking when you look at when Forerunner invested.
The firm first backed Oura in March 2020, when the company was valued at around $725 million.
At the midpoint IPO price, Oura’s fully diluted valuation would be about $14.9 billion.
So Forerunner is looking to exit a significant investment after Oura’s valuation has increased dramatically.
Lifeline Ventures is also taking money off the table
Another early investor, Lifeline Ventures, is selling roughly one-third of its Oura position.
Lifeline was one of Oura’s earliest backers, investing in the company during its 2015 seed round, when Oura was valued at around $6.1 million.
The firm plans to sell close to 7 million shares.
At $42 per share, that stake would be worth approximately $292 million.
That gives some perspective on how dramatically Oura’s value has changed since its early days.
From a startup valued at just a few million dollars to a company potentially valued at nearly $15 billion, early investors are now sitting on very different numbers.
The Dodgers’ investment arm is selling too
Elysian Park Ventures, the private investment arm associated with the Los Angeles Dodgers, is also selling a significant portion of its Oura holdings.
Elysian Park first invested during Oura’s 2021 Series C, when the company was valued at around $900 million.
It plans to sell approximately 61.5% of its total stake.
At the midpoint IPO price, the shares being sold would be worth around $36.6 million.
Together, these transactions show that several early backers are using the IPO as an opportunity to realize part of their investments.
Not every major investor is selling
The selling is not happening across Oura’s entire investor base.
Fidelity Investments, Oura’s largest shareholder with a 10.9% stake, is not selling any shares in the IPO.
Other major investors, including Temasek, Iconiq Capital and Atreides, also appear to be selling little or nothing.
That creates an interesting split among Oura’s backers.
Some early investors are taking the opportunity to cash out, while several major shareholders are continuing to hold their positions.
Oura itself is raising money too
It is important to separate the two sides of the offering.
Oura plans to sell 13.5 million new shares, while existing shareholders plan to sell 36.5 million shares.
That adds up to the total 50 million shares being offered.
The money raised from the new shares goes to Oura.
The proceeds from shares sold by existing shareholders go to those investors instead.
So while the IPO could raise up to $2.2 billion in total, a substantial portion of that money is not going directly into Oura’s balance sheet.
That is one of the most important details for investors to understand.
From Kickstarter project to nearly $15 billion valuation
Oura’s journey is notable.
Founded in Finland in 2013 and now headquartered in San Francisco, the company started as a Kickstarter project and helped turn smart rings into a recognizable category in the wearable technology market.
Its growth accelerated during the pandemic.
Oura rings gained additional visibility after being used by the NBA during its bubble season, where the devices were used as part of efforts to monitor player health.
Since then, Oura has expanded beyond basic activity tracking.
Its rings track metrics related to:
- Sleep
- Activity
- Stress
- Recovery
- Heart health
- Other wellness measurements
The company has also been expanding its broader health and wellness ecosystem.
Revenue growth is a major part of the IPO story
Oura is not entering the public markets as a small startup hoping to prove its business model.
According to its filing, the company generated $1.21 billion in revenue during the first nine months of 2026, compared with $697.6 million during the same period in 2025.
That represents approximately 74% year-over-year growth.
The business combines hardware sales with recurring membership revenue, giving Oura a model that extends beyond simply selling a wearable device.
That recurring membership component is an important part of the company’s strategy as it expands its health and wellness platform.
But Oura is moving closer to regulated healthcare
There is another part of the IPO story investors will be watching.
Oura has been expanding its health-related capabilities, but there is a line between wellness technology and regulated medical devices.
At present, Oura says its existing features fall under the FDA’s wellness exemption and are not cleared as medical devices.
The company is also working on new health-related capabilities.
For example, Oura has said it plans to offer a feature for tracking nighttime blood pressure trends.
It is also studying technology designed to identify hidden hypertension risk.
The regulatory distinction matters because some health features could eventually require FDA review.
Oura itself has warned investors that there is no guarantee the FDA will continue to consider every relevant feature exempt from medical-device regulations.
Oura is building a broader health ecosystem
The company’s strategy is also moving beyond the ring itself.
Oura has introduced features that allow users to upload bloodwork results and has formed partnerships with companies including Dexcom and ResMed.
That points toward a broader ambition for Oura.
The ring is becoming a way to collect health and wellness data, while the company’s software and partnerships could potentially make that information more useful across different parts of a user’s health journey.
At the same time, expanding into health brings additional regulatory and accuracy considerations.
There is also a legal issue to watch
Oura is going public while facing a proposed class-action lawsuit related to claims about the accuracy of its sleep-tracking features.
That does not determine the outcome of the company’s IPO, but it is another factor investors will need to consider when assessing the business.
For a company whose value proposition depends heavily on health and wellness data, questions around measurement accuracy can be particularly important.
The bigger IPO question
Oura’s IPO is about more than a smart ring.
It is a story about what happens when a successful private company reaches the public markets and early investors finally get a chance to realize years of gains.
At a potential valuation of around $14.9 billion, Oura would be entering the public market at a very different scale from the company that raised its first seed round in 2015.
But the IPO also gives investors a chance to examine the business more closely.
How sustainable is the company’s rapid revenue growth?
Can Oura turn its hardware into a durable health and wellness platform?
How will regulatory requirements evolve as its products move closer to medical applications?
And perhaps most importantly, can Oura maintain its momentum once it becomes a public company?
For early venture investors, the IPO represents a major liquidity event.
For public-market investors, it will be the beginning of a new chapter where Oura’s growth, profitability, competition and regulatory exposure will be visible to the broader market.
Oura started with a ring. Now, it is asking public investors to value the entire health and wellness ecosystem being built around it.